Go Deep
Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 21,691 | -4.6 | 1.99 | 0.21 | 195.23 |
| Oct 2026 | 21,510 | -4.8 | 2.10 | 0.21 | 205.09 |
| Oct 2026 | 21,510 | -4.6 | 2.10 | 0.21 | 205.12 |
| Oct 2026 | 21,674 | -4.6 | 2.00 | 0.21 | 195.11 |
| Oct 2026 | 20,735 | -5.8 | 2.55 | 0.21 | 249.37 |
| Oct 2026 | 20,867 | -5.7 | 2.48 | 0.21 | 241.78 |
| Oct 2026 | 20,603 | -6.0 | 2.63 | 0.21 | 256.32 |
| Oct 2026 | 20,785 | -5.8 | 2.52 | 0.21 | 245.42 |
| Oct 2026 | 19,730 | -7.2 | 3.15 | 0.21 | 307.09 |
Nautilus Biotechnology, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 10,000.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -14,469,000.0 | -14,697,000.0 | -13,781,000.0 | -13,574,000.0 |
| EPS | -0.1 | -0.1 | -0.1 | -0.1 |
Nautilus Biotechnology, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -59,001,000.0 | -70,780,000.0 | -63,675,000.0 | -57,924,000.0 |
| EPS | -0.5 | -0.6 | -0.5 | -0.5 |
Nautilus Biotechnology, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 191,112,000.0 | 242,743,000.0 | 305,565,000.0 | 350,052,000.0 | — |
| Total Liabilities | 34,139,000.0 | 34,013,000.0 | 40,212,000.0 | 35,128,000.0 | — |
| Total Equity | 156,973,000.0 | 208,730,000.0 | 265,353,000.0 | 314,924,000.0 | — |
Owes vs Owns
Nautilus Biotechnology, Inc. owed $0.20 for every $1 it owned in Jun 2026, up from $0.10 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.20× | 0.18× | 0.14× | 0.13× | 0.10× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Nautilus Biotechnology, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 54.1%Fixed assets (tangible) 16.3%Long-term investments 27.6%Other assets 2.0%
How it's funded — Dec 2025
Short-term debt 2.0%Long-term debt 13.7%Other liabilities 1.7%Shareholders' equity 82.1%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 103.4 | 129.9 | 173.4 | 184.5 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 31.2 | 32.3 | 36.9 | 32.6 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 52.7 | 76.4 | 90.6 | 129.2 |
| Other assets | 3.7 | 4.1 | 4.6 | 3.8 |
| Liabilities & equity | ||||
| Short-term debt | 3.8 | 4.1 | 3.5 | 2.0 |
| Long-term debt | 26.2 | 26.4 | 31.1 | 28.3 |
| Payables | 0.9 | 1.0 | 1.6 | 1.3 |
| Other liabilities | 3.2 | 2.5 | 3.9 | 3.5 |
| Shareholders' equity | 157.0 | 208.7 | 265.4 | 314.9 |
| Net tangible assets | 157.0 | 208.7 | 265.4 | 314.9 |
Nautilus Biotechnology, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -50,696,000.0 | -59,145,000.0 | -51,711,000.0 | -45,806,000.0 | — |
| Investing Activities | 35,224,000.0 | 66,250,000.0 | -43,735,000.0 | -25,740,000.0 | — |
| Financing Activities | 214,000.0 | 1,144,000.0 | 368,000.0 | 562,000.0 | — |